UniSuper Management Pty Ltd Has $9.28 Million Stock Position in Pfizer Inc. (NYSE:PFE)

UniSuper Management Pty Ltd grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 34.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 349,745 shares of the biopharmaceutical company's stock after buying an additional 90,289 shares during the period. UniSuper Management Pty Ltd's holdings in Pfizer were worth $9,279,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer in the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC bought a new position in Pfizer during the 4th quarter worth $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer during the fourth quarter worth $28,000. Noble Wealth Management PBC bought a new stake in shares of Pfizer in the fourth quarter valued at about $31,000. Finally, Curio Wealth LLC bought a new position in Pfizer during the fourth quarter worth about $32,000. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on PFE. Truist Financial decreased their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Bank of America reaffirmed a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, Citigroup decreased their price target on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, Pfizer currently has an average rating of "Moderate Buy" and a consensus target price of $31.92.

Remove Ads

Pfizer Price Performance

Shares of PFE traded up $0.19 during trading hours on Friday, reaching $25.20. The stock had a trading volume of 32,322,049 shares, compared to its average volume of 39,037,478. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The stock has a market capitalization of $142.93 billion, a PE ratio of 17.87, a PEG ratio of 0.64 and a beta of 0.61. The company's 50-day moving average is $26.06 and its two-hundred day moving average is $26.92.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's revenue was up 24.7% compared to the same quarter last year. During the same period last year, the company earned $0.10 EPS. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by company insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.